Paliperidone for irritability in adolescents and young adults with autistic disorder

Kimberly A. Stigler, Jennifer E. Mullett, Craig A. Erickson, David J. Posey, Christopher J. McDougle

Research output: Contribution to journalArticle

40 Scopus citations


Rationale Individuals with autistic disorder (autism) frequently exhibit significant irritability marked by severe tantrums, aggression, and self-injury. Despite advances in the treatment of this symptom domain in autism, there remains an ongoing need for more effective and better tolerated pharmacotherapies. Objectives The aim of this study is to determine the effectiveness and tolerability of paliperidone for irritability in autism. Methods This is a prospective, 8-week open-label study of paliperidone in 25 adolescents and young adults with autism. Primary outcome measures included the Clinical Global Impressions-Improvement (CGI-I) Scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). Concomitant medications (except antipsychotics) were permitted if dosages were stable for ≥2 months. Results Twenty-one (84 %) of 25 subjects ages 12-21 years (mean 15.3 years) responded to paliperidone, based on a CGII Scale score of 1 or 2 (very much or much improved) and ≥25 % improvement on the ABC-I. The mean final dosage of paliperidone was 7.1 mg/day (range 3-12 mg/day). Two subjects discontinued paliperidone prior to study completion (moderate sedation, n01; nonresponse, n01). Mild-tomoderate extrapyramidal symptoms were recorded in four subjects. A mean weight gain of 2.2 ± 2.6 kg (range -3.6 to +7.9 kg) was recorded. Mean age- and sex-normed body mass index increased from 23.6 to 24.2 (p≤ 0.001). Mean serum prolactin increased from 5.3 to 41.4 ng/mL (p≤0.0001). Conclusions Paliperidone treatment was associated with significant improvement in irritability and was generally well tolerated. Larger scale, placebo-controlled studies are needed to elucidate the efficacy and tolerability of paliperidone in this population.

Original languageEnglish (US)
Pages (from-to)237-245
Number of pages9
Issue number2
StatePublished - Sep 1 2012


  • Autistic disorder
  • Irritability
  • Paliperidone

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Paliperidone for irritability in adolescents and young adults with autistic disorder'. Together they form a unique fingerprint.

  • Cite this

    Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology, 223(2), 237-245.